Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 2Phase 4 1Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 1Sarcoma 1Neoplasms 1Esophageal Squamous Cell Carcinoma 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Medullary 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

Doxorubicin 3Radiotherapy 2Drug Therapy 2pirarubicin 1pazopanib 1liposomal doxorubicin 1capmatinib 1anlotinib 1Triptorelin Pamoate 1Trabectedin 1Radiation 1Methotrexate 1Ifosfamide 1Fatty Acids, Omega-3 1Cisplatin 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Sarcoma × anlotinib × Clear all
NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
233 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡